FDA Approves RYZUMVI, First Non-Cholinergic Prescription Eye Drop for Presbyopia
Start here
On October 16, 2026, the FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%), developed by Viatris and Opus Genetics, for presbyopia in adults. It is the first prescription eye drop for the condition that works without relying on the cholinergic pathway, distinguishing it from existing miotic approaches to age-related near-vision loss. The approval gives the roughly presbyopia-affected adult population a new pharmacologic option. Open questions at this stage include how the launch will proceed, payer positioning, and how clinicians adopt a non-cholinergic mechanism for routine presbyopia management.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickFDA approves RYZUMVI, the first non-cholinergic prescription eye drop for presbyopia
On October 16, 2026, the FDA approved RYZUMVI (phentolamine ophthalmic solution 0.75%) from Viatris and Opus Genetics for presbyopia in adults. It is the first prescription eye drop for the condition that does not rely on the cholinergic pathway.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 19 13:00)·Change over 24h in the comparable set +376%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.